Learning from the past: development of safe and effective COVID-19 vaccines

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Another coronavirus, another epidemic, another warning

(2020) Gregory A. Poland   VACCINE

On the origin and continuing evolution of SARS-CoV-2

(2020) Xiaolu Tang et al.   National Science Review

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Identification of Human Single-Domain Antibodies against SARS-CoV-2

(2020) Yanling Wu et al.   Cell Host & Microbe

Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

(2020) Jiuxin Qu et al.   CLINICAL INFECTIOUS DISEASES

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

(2020) Wei-jie Guan et al.   EUROPEAN RESPIRATORY JOURNAL

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

(2020) Ling Ni et al.   IMMUNITY

Immunology of COVID-19: current state of the science

(2020) Nicolas Vabret et al.   IMMUNITY

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

(2020) Kristi Williams et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

(2020) Till Koch et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

(2020) Pedro M Folegatti et al.   LANCET INFECTIOUS DISEASES

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

(2020) Kelvin Kai-Wang To et al.   LANCET INFECTIOUS DISEASES

Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

(2020) Shibo Jiang   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Coronavirus vaccines: five key questions as trials begin

(2020) Ewen Callaway   NATURE

The COVID-19 vaccine development landscape

(2020) Tung Thanh Le et al.   NATURE REVIEWS DRUG DISCOVERY

Rapid COVID-19 vaccine development

(2020) Barney S. Graham   SCIENCE

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

(2020) Jingyou Yu et al.   SCIENCE

Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines

(2020) Paul-Henri Lambert et al.   VACCINE

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

(2020) Kun Li et al.   mBio

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

(2020) Christopher M Petrilli et al.   BMJ-British Medical Journal

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

(2020) Israel Júnior Borges do Nascimento et al.   Journal of Clinical Medicine

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

(2020) Hui Wang et al.   CELL

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

(2020) Lianpan Dai et al.   CELL

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

A Thermostable mRNA Vaccine against COVID-19

(2020) Na-Na Zhang et al.   CELL

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

(2020) Wanbo Tai et al.   CELL RESEARCH

SARS-CoV-2 vaccines: ‘Warp Speed’ needs mind melds not warped minds

(2020) John P. Moore et al.   JOURNAL OF VIROLOGY

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

(2020) Jennifer A. Juno et al.   NATURE MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad neutralization of SARS-related viruses by human monoclonal antibodies

(2020) Anna Z. Wec et al.   SCIENCE

Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2

(2020) Yvonne C. F. Su et al.   mBio

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice

(2020) Leslie van der Fits et al.   npj Vaccines

Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity

(2020) Barnaby E Young et al.   CLINICAL INFECTIOUS DISEASES

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

(2020) Jan Van Elslande et al.   CLINICAL INFECTIOUS DISEASES

Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

(2020) Kelvin Kai-Wang To et al.   CLINICAL INFECTIOUS DISEASES

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Humoral Immune Response to SARS-CoV-2 in Iceland

(2020) Daniel F. Gudbjartsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

(2019) Kayvon Modjarrad et al.   LANCET INFECTIOUS DISEASES

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

(2019) Chean Yeah Yong et al.   Frontiers in Microbiology

Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes

(2019) Stanislav O. Fedechkin et al.   JOURNAL OF VIROLOGY

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

(2019) Yushun Wan et al.   JOURNAL OF VIROLOGY

Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy

(2018) Saranya Sridhar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reconstruction of antibody dynamics and infection histories to evaluate dengue risk

(2018) Henrik Salje et al.   NATURE

Cellular Immune Correlates Preventing Disease Against Respiratory Syncytial Virus by Vaccination with Virus-Like Nanoparticles Carrying Fusion Proteins

(2017) Young-Tae Lee et al.   Journal of Biomedical Nanotechnology

Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant

(2017) Kirsten Schneider-Ohrum et al.   JOURNAL OF VIROLOGY

Antibody-dependent enhancement of severe dengue disease in humans

(2017) Leah C. Katzelnick et al.   SCIENCE

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

(2017) Katherine V. Houser et al.   PLoS Pathogens

Vaccines for the prevention against the threat of MERS-CoV

(2016) Lanying Du et al.   Expert Review of Vaccines

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines

(2016) Lanying Du et al.   Nature Communications

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

(2016) Anurodh Shankar Agrawal et al.   Human Vaccines & Immunotherapeutics

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

(2016) Qidi Wang et al.   ACS Infectious Diseases

Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America

(2015) Luis Villar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

(2015) Joan O. Ngwuta et al.   Science Translational Medicine

Research on Dengue During World War II Revisited

(2014) Grace E. Snow et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

(2014) Sheng-Fan Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV

(2014) F. Yasui et al.   JOURNAL OF IMMUNOLOGY

Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection

(2014) L. Du et al.   JOURNAL OF IMMUNOLOGY

Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies

(2014) Tianlei Ying et al.   JOURNAL OF VIROLOGY

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

(2014) Maria Rosario Capeding et al.   LANCET

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus

(2014) Ming Yip et al.   Virology Journal

Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate

(2013) Wen-Hsiang Chen et al.   Human Vaccines & Immunotherapeutics

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

(2012) M. Magro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines

(2012) Shibo Jiang et al.   Emerging Microbes & Infections

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

(2011) M. Bolles et al.   JOURNAL OF VIROLOGY

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

(2011) Melissa M. Coughlin et al.   REVIEWS IN MEDICAL VIROLOGY

Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years

(2011) Peter L. Collins et al.   VIRUS RESEARCH

The Human Antibody Response to Dengue Virus Infection

(2011) Wahala M. P. B. Wahala et al.   Viruses-Basel

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

(2010) Jody D. Berry et al.   mAbs

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

(2009) Lanying Du et al.   NATURE REVIEWS MICROBIOLOGY

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

(2008) Julie E. Martin et al.   VACCINE